October 23, 2025 – Talk Bio

RAPT Therapeutics; public offering; common stock; underwritten offering; biopharmaceutical; immunology; market conditions; share dilution; offering pricing; gross proceeds

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

1 day ago talkbio0Tagged ACR-2316, Acrivon, AP3, Conferences, Generative Phosphoproteomics, Inhibitor, KaiSR, partial response, PKMYT1 protein, human, Platform, PLK1 gene, precision oncology, preclinical data, Study models, WEE1 inhibitor

Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology

Eye Disease Biotech Kala Bio Collapses After Failed Clinical Trial, Lender Takes Control

1 day ago talkbio0Tagged Clinical trial failure, Corneal epithelial defect, Experimental drug, foreclosure proceedings, Kala Bio, KPI-012, lender takeover, Oxford Finance, PCED, Persistent, Shock, Workforce reduction

Kala Bio; biotech collapse; failed drug trial; KPI-012; persistent corneal epithelial defect; PCED; lender takeover; Oxford Finance; foreclosure proceedings; workforce reduction; clinical trial failure

Arcturus Therapeutics Stock Crashes 60% on Underwhelming mRNA Cystic Fibrosis Drug Results

1 day ago talkbio0Tagged ARCT-032, Arcturus Therapeutics ', clinical trial results, Cystic Fibrosis, mRNA therapy, Respiratory physiology, safety profile, Stock Crash, Volume^at 1.0 s post forced expiration:Volume:Point in time:Respiratory system:Quantitative

Arcturus Therapeutics; ARCT-032; cystic fibrosis; mRNA therapy; stock crash; clinical trial results; lung function; FEV1; safety profile

Alkermes Acquires Avadel Pharmaceuticals for $2.1B, Gaining Sleep Drug LUMRYZ and Setting Strategic Evolution

1 day ago talkbio0Tagged Acquisition, Alkermes, Avadel Pharmaceuticals, Biological Factors, LUMRYZ, Narcolepsy, portfolio, premium, Rare Diseases, Sleep medicine specialist, strategic

Alkermes; Avadel Pharmaceuticals; acquisition; LUMRYZ; narcolepsy; sleep medicine; strategic portfolio; biopharmaceuticals; rare disease; deal premium

Flagship Pioneering Launches Expedition Medicines to Revolutionize Small-Molecule Drug Discovery with AI

2 days ago talkbio0Tagged AI drug discovery, covalent binding drugs, executive leadership, Expedition Medicines, Flagship, generative design, Lila Sciences, Small Molecule, startup

Flagship Pioneering; Expedition Medicines; AI drug discovery; small molecules; covalent binding drugs; Lila Sciences; biotech startup; generative design; executive leadership

Terns Ditches Obesity Pill After Phase 2 Letdown, Shifts Focus to Cancer Pipeline

2 days ago talkbio0Tagged liver enzyme elevation, Metabolic Diseases, Myeloid Leukemia, Chronic, Neoplasms, Obesity Drug, Phase 2 trial, Product containing glucagon-like peptide 1 receptor agonist (product), TERN-601, TERN-701, Terns, Weight Loss

Terns Pharmaceuticals; TERN-601; obesity drug; GLP-1 receptor agonist; Phase 2 trial; weight loss; liver enzyme elevation; oncology; TERN-701; chronic myeloid leukemia (CML); metabolic disease